madrigal pharmaceuticals inc - MDGL
MDGL
Close Chg Chg %
440.75 -0.82 -0.19%
Closed Market
439.93
-0.82 (0.19%)
Volume: 689.97K
Last Updated:
Sep 19, 2025, 4:00 PM EDT
Company Overview: madrigal pharmaceuticals inc - MDGL
MDGL Key Data
| Open $442.06 | Day Range 435.41 - 447.57 |
| 52 Week Range 200.63 - 457.16 | Market Cap $9.82B |
| Shares Outstanding 22.29M | Public Float 20.17M |
| Beta -1.02 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$12.85 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 364.19K |
MDGL Performance
| 1 Week | 1.78% | ||
| 1 Month | 6.09% | ||
| 3 Months | 53.97% | ||
| 1 Year | 88.41% | ||
| 5 Years | 272.22% |
MDGL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
16
Full Ratings ➔
About madrigal pharmaceuticals inc - MDGL
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
MDGL At a Glance
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
West Conshohocken, Pennsylvania 19428
| Phone | 1-267-824-2827 | Revenue | 180.13M | |
| Industry | Pharmaceuticals: Major | Net Income | -465,892,000.00 | |
| Sector | Health Technology | Employees | 528 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
MDGL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 36.441 |
| Price to Book Ratio | 9.001 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.58 |
| Enterprise Value to Sales | 31.935 |
| Total Debt to Enterprise Value | 0.021 |
MDGL Efficiency
| Revenue/Employee | 341,160.985 |
| Income Per Employee | -882,371.212 |
| Receivables Turnover | 3.347 |
| Total Asset Turnover | 0.214 |
MDGL Liquidity
| Current Ratio | 6.102 |
| Quick Ratio | 5.901 |
| Cash Ratio | 5.501 |
MDGL Profitability
| Gross Margin | 95.931 |
| Operating Margin | -276.393 |
| Pretax Margin | -258.638 |
| Net Margin | -258.638 |
| Return on Assets | -55.371 |
| Return on Equity | -80.346 |
| Return on Total Capital | -53.309 |
| Return on Invested Capital | -66.796 |
MDGL Capital Structure
| Total Debt to Total Equity | 15.85 |
| Total Debt to Total Capital | 13.682 |
| Total Debt to Total Assets | 11.472 |
| Long-Term Debt to Equity | 15.72 |
| Long-Term Debt to Total Capital | 13.569 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Madrigal Pharmaceuticals Inc - MDGL
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | 180.13M | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 405.00K | 467.00K | 527.00K | 7.33M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 405.00K | 467.00K | 527.00K | 1.10M | |
Depreciation
| - | 405.00K | 467.00K | 527.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| -14.01% | +15.31% | +12.85% | +1,290.70% | |
Gross Income
| (405.00K) | (467.00K) | (527.00K) | 172.80M | |
Gross Income Growth
| +14.01% | -15.31% | -12.85% | +32,890.13% | |
Gross Profit Margin
| - | - | - | +95.93% | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 241.58M | 293.10M | 379.97M | 670.68M | |
Research & Development
| 205.16M | 244.97M | 271.82M | 235.62M | |
Other SG&A
| 36.41M | 48.13M | 108.15M | 435.06M | |
SGA Growth
| +17.36% | +21.33% | +29.64% | +76.51% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 500.00K | - |
EBIT after Unusual Expense
| (242.48M) | (293.57M) | (380.50M) | (497.88M) | |
Non Operating Income/Expense
| 636.00K | 2.19M | 19.58M | 46.65M | |
Non-Operating Interest Income
| 363.00K | 2.19M | 19.58M | 46.65M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 3.96M | 12.71M | 14.67M | |
Interest Expense Growth
| - | - | +220.69% | +15.41% | - |
Gross Interest Expense
| - | 3.96M | 12.71M | 14.67M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (241.85M) | (295.35M) | (373.63M) | (465.89M) | |
Pretax Income Growth
| -19.58% | -22.12% | -26.50% | -24.69% | |
Pretax Margin
| - | - | - | -258.64% | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (241.85M) | (295.35M) | (373.63M) | (465.89M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (241.85M) | (295.35M) | (373.63M) | (465.89M) | |
Net Income Growth
| -19.58% | -22.12% | -26.50% | -24.69% | |
Net Margin Growth
| - | - | - | -258.64% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (241.85M) | (295.35M) | (373.63M) | (465.89M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (241.85M) | (295.35M) | (373.63M) | (465.89M) | |
EPS (Basic)
| -14.6261 | -17.2344 | -19.9933 | -21.9007 | |
EPS (Basic) Growth
| -11.71% | -17.83% | -16.01% | -9.54% | |
Basic Shares Outstanding
| 16.54M | 17.14M | 18.69M | 21.27M | |
EPS (Diluted)
| -14.6261 | -17.2344 | -19.9933 | -21.9007 | |
EPS (Diluted) Growth
| -11.71% | -17.83% | -16.01% | -9.54% | |
Diluted Shares Outstanding
| 16.54M | 17.14M | 18.69M | 21.27M | |
EBITDA
| (241.58M) | (293.10M) | (379.97M) | (496.78M) | |
EBITDA Growth
| -17.36% | -21.33% | -29.64% | -30.74% | |
EBITDA Margin
| - | - | - | -275.78% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 472.467 | |
| Number of Ratings | 16 | Current Quarters Estimate | -1.933 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | -9.292 | |
| Last Quarter’s Earnings | -1.90 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -21.90 | Next Fiscal Year Estimate | 3.847 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 15 | 16 | 16 |
| Mean Estimate | -1.93 | -2.16 | -9.29 | 3.85 |
| High Estimates | -0.09 | 0.56 | -4.79 | 19.52 |
| Low Estimate | -6.95 | -7.95 | -15.26 | -6.90 |
| Coefficient of Variance | -102.37 | -145.42 | -40.25 | 229.83 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 14 | 15 | 14 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Madrigal Pharmaceuticals Inc - MDGL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Madrigal Pharmaceuticals Inc - MDGL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 17, 2025 | Fred Bernard Craves Director | 357,804 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $111.06 per share | 39,737,712.24 |
| Mar 17, 2025 | Fred Bernard Craves Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2025 | Fred Bernard Craves Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2025 | Fred Bernard Craves Director | 7,742 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2025 | Fred Bernard Craves Director | 350,076 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $330.22 per share | 115,602,096.72 |
| Mar 17, 2025 | Fred Bernard Craves Director | 350,151 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $329.86 per share | 115,500,808.86 |
| Mar 17, 2025 | Fred Bernard Craves Director | 351,118 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $328.68 per share | 115,405,464.24 |
| Mar 17, 2025 | Fred Bernard Craves Director | 351,518 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $327.63 per share | 115,167,842.34 |
| Mar 17, 2025 | Fred Bernard Craves Director | 352,518 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $325.63 per share | 114,790,436.34 |
| Mar 17, 2025 | Fred Bernard Craves Director | 353,318 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $324.69 per share | 114,718,821.42 |
| Mar 17, 2025 | Fred Bernard Craves Director | 354,218 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $323.47 per share | 114,578,896.46 |
| Mar 17, 2025 | Fred Bernard Craves Director | 355,867 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $322.45 per share | 114,749,314.15 |
| Mar 17, 2025 | Fred Bernard Craves Director | 357,818 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.06 per share | 23,279,639.08 |
| Mar 17, 2025 | Fred Bernard Craves Director | 350,076 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $334.97 per share | 117,264,957.72 |
| Mar 17, 2025 | Fred Bernard Craves Director | 350,276 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $333.66 per share | 116,873,090.16 |
| Mar 17, 2025 | Fred Bernard Craves Director | 351,076 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $332.38 per share | 116,690,640.88 |
| Mar 17, 2025 | Fred Bernard Craves Director | 353,458 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $331.36 per share | 117,121,842.88 |
| Mar 17, 2025 | Fred Bernard Craves Director | 356,217 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $330.54 per share | 117,743,967.18 |
| Mar 17, 2025 | Fred Bernard Craves Director | 351,804 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.06 per share | 22,888,368.24 |
| Mar 6, 2025 | Shannon Kelley General Counsel | 7,290 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $335 per share | 2,442,150.00 |